Literature DB >> 28645799

Genotype-phenotype evaluation of MED13L defects in the light of a novel truncating and a recurrent missense mutation.

Reza Asadollahi1, Markus Zweier1, Laura Gogoll1, Raphael Schiffmann2, Heinrich Sticht3, Katharina Steindl1, Anita Rauch4.   

Abstract

A decade after the designation of MED13L as a gene and its link to intellectual disability (ID) and dextro-looped transposition of great arteries in 2003, we previously described a recognizable syndrome due to MED13L haploinsufficiency. Subsequent reports of 22 further patients diagnosed by genome-wide testing further delineated the syndrome with expansion of the phenotypic spectrum and showed reduced penetrance for congenital heart defects. We now report two novel patients identified by whole exome sequencing, one with a de novo MED13L truncating mutation and the other with a de novo missense mutation. The first patient indicates some facial resemblance to Kleefstra syndrome as a novel differential diagnosis, and the second patient shows, for the first time, recurrence of a MED13L missense mutation (p.(Asp860Gly)). Notably, our in silico modelling predicted this missense mutation to decrease the stability of an alpha-helix and thereby affecting the MED13L secondary structure, while the majority of published missense mutations remain variants of uncertain significance. Review of the reported patients with MED13L haploinsufficiency indicates moderate to severe ID and facial anomalies in all patients, as well as severe speech delay and muscular hypotonia in the majority. Further common signs include abnormal MRI findings of myelination defects and abnormal corpus callosum, ataxia and coordination problems, autistic features, seizures/abnormal EEG, or congenital heart defects, present in about 20-50% of the patients. With reference to facial anomalies, the majority of patients were reported to show broad/prominent forehead, low set ears, bitemporal narrowing, upslanting palpebral fissures, depressed/flat nasal bridge, bulbous nose, and abnormal chin, but macroglossia and horizontal eyebrows were also observed in ∼30%. The latter are especially important in the differential diagnosis of 1p36 deletion and Kleefstra syndromes, while the more common facial gestalt shows some resemblance to 22q11.2 deletion syndrome. Despite the fact that MED13L was found to be one of the most common ID genes in the Deciphering Developmental Disorders Study, further detailed patient descriptions are needed to explore the full clinical spectrum, potential genotype-phenotype correlations, as well as the role of missense mutations and potential mutational hotspots along the gene.
Copyright © 2017 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Haploinsufficiency; Intellectual disability; MED13L

Mesh:

Substances:

Year:  2017        PMID: 28645799     DOI: 10.1016/j.ejmg.2017.06.004

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  17 in total

1.  Co-occurring medical conditions among individuals with ASD-associated disruptive mutations.

Authors:  Evangeline C Kurtz-Nelson; Jennifer S Beighley; Caitlin M Hudac; Jennifer Gerdts; Arianne S Wallace; Kendra Hoekzema; Evan E Eichler; Raphael A Bernier
Journal:  Child Health Care       Date:  2020-03-17

2.  MED13L-related intellectual disability: involvement of missense variants and delineation of the phenotype.

Authors:  T Smol; F Petit; A Piton; B Keren; D Sanlaville; A Afenjar; S Baker; E C Bedoukian; E J Bhoj; D Bonneau; E Boudry-Labis; S Bouquillon; O Boute-Benejean; R Caumes; N Chatron; C Colson; C Coubes; C Coutton; F Devillard; A Dieux-Coeslier; M Doco-Fenzy; L J Ewans; L Faivre; E Fassi; M Field; C Fournier; C Francannet; D Genevieve; I Giurgea; A Goldenberg; A K Green; A M Guerrot; D Heron; B Isidor; B A Keena; B L Krock; P Kuentz; E Lapi; N Le Meur; G Lesca; D Li; I Marey; C Mignot; C Nava; A Nesbitt; G Nicolas; C Roche-Lestienne; T Roscioli; V Satre; A Santani; M Stefanova; S Steinwall Larsen; P Saugier-Veber; S Picker-Minh; C Thuillier; A Verloes; G Vieville; M Wenzel; M Willems; S Whalen; Y A Zarate; A Ziegler; S Manouvrier-Hanu; V M Kalscheuer; B Gerard; Jamal Ghoumid
Journal:  Neurogenetics       Date:  2018-03-06       Impact factor: 2.660

3.  Language and Cognitive Impairment Associated with a Novel p.Cys63Arg Change in the MED13L Transcriptional Regulator.

Authors:  Salud Jiménez-Romero; Pilar Carrasco-Salas; Antonio Benítez-Burraco
Journal:  Mol Syndromol       Date:  2018-01-11

4.  Mutations in Mediator Complex Genes CDK8, MED12, MED13, and MEDL13 Mediate Overlapping Developmental Syndromes.

Authors:  Martin Poot
Journal:  Mol Syndromol       Date:  2019-08-16

5.  Genetic study links components of the autonomous nervous system to heart-rate profile during exercise.

Authors:  Niek Verweij; Yordi J van de Vegte; Pim van der Harst
Journal:  Nat Commun       Date:  2018-03-01       Impact factor: 14.919

Review 6.  Report of a de novo c.2605C > T (p.Pro869Ser) change in the MED13L gene and review of the literature for MED13L-related intellectual disability.

Authors:  Zhi Yi; Ying Zhang; Zhenfeng Song; Hong Pan; Chengqing Yang; Fei Li; Jiao Xue; Zhenghai Qu
Journal:  Ital J Pediatr       Date:  2020-07-09       Impact factor: 2.638

7.  Analysis of Polymorphisms in the Mediator Complex Subunit 13-like (Med13L) Gene in the Context of Immune Function and Development of Experimental Arthritis.

Authors:  Samra Sardar; Katrine Kanne; Åsa Andersson
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2018-06-27       Impact factor: 4.291

8.  Clinical relevance of targeted exome sequencing in patients with rare syndromic short stature.

Authors:  Gilyazetdinov Kamil; Ju Young Yoon; Sukdong Yoo; Chong Kun Cheon
Journal:  Orphanet J Rare Dis       Date:  2021-07-03       Impact factor: 4.123

9.  A complex molecular switch directs stress-induced cyclin C nuclear release through SCFGrr1-mediated degradation of Med13.

Authors:  David C Stieg; Stephen D Willis; Vidyaramanan Ganesan; Kai Li Ong; Joseph Scuorzo; Mia Song; Julianne Grose; Randy Strich; Katrina F Cooper
Journal:  Mol Biol Cell       Date:  2017-12-06       Impact factor: 4.138

10.  MED13L integrates Mediator-regulated epigenetic control into lung cancer radiosensitivity.

Authors:  Nasha Zhang; Yemei Song; Yeyang Xu; Jiandong Liu; Yue Shen; Liqing Zhou; Jinming Yu; Ming Yang
Journal:  Theranostics       Date:  2020-07-23       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.